Atherosclerosis risk and CV risk reduction in GLP1-RA treated patients

Czech version

Authors: Matej Samoš ^1,2,3
Authors‘ workplace: I. interná klinika JLF UK a UNM, Martin ¹; Pracovisko invazívnej a intervenčnej kardiológie, FN s poliklinikou Žilina ²; Oddelenie akútnej a intervenčnej kardiológie, Stredoslovenský ústav srdcových a cievnych chorôb (SÚSCCH), a. s., Banská Bystrica ³
Published in: AtheroRev 2026; 11(1): 41-43
Category: Reviews

Overview

Glucagon like peptide 1 receptor agonists (GLP1-RA) have expanded their therapeutic indications as agents for pharmacological treatment of obesity, while it appears that their will become a drug of choice also for prevention and treatment of atherosclerotic cardiovascular diseases (ASCVD). These data come from repeatedly documented cardiovascular benefit (which overcomes the weight-reduction benefit itself) of these agents. Semaglutide, a modern, long-acting GLP1-RA had demonstrated very positive and promising results in several marketing and post-marketing clinical trials. The article summarizes the most novel knowledge regarding the benefit of GLP1-RA in reduction of ASCVD risk and the reduction of overall CV risk which were documented in recent clinical studies with GLP1-RA, mostly using long-acting GLP1-RA semaglutide administration.

Keywords:

semaglutide – Atherosclerosis – cardiovascular risk – atherosclerotic cardiovascular diseases – GLP1 receptor agonists (GLP1-RA)

Sources

1. Tkáč I. Agonisty GLP1receptorov: antidiabetiká s antiaterogénnym účinkom. AtheroRev 2020; 5(3): 181–184.

2. Yang HM. GLP1 Agonists in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies. J Clin Med 2025; 14(19): 6758. Dostupné z DOI: <http://dx.doi.org/10.3390/jcm14196758>.

3. Marso SP, Bain SC, Consoli A et al. [SUSTAIN6 Investigators]. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016; 375(19): 1834–1844. Dostupné z DOI: <http://dx.doi. org/10.1056/NEJMoa1607141>.

4. Smolderen KG, MenaHurtado C, Zhao Z et al. Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the realworld: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World). Diabetes Obes Metab 2025; 27(11): 6691–6704. Dostupné z DOI: <http:// dx.doi.org/10.1111/dom.70080>.

5. Lincoff AM, BrownFrandsen K, Colhoun HM et al. [SELECT Trial Investigators]. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023; 389(24): 2221–2232. Dostupné z DOI: <http:// dx.doi.org/10.1056/NEJMoa2307563>.

6. Deanfield J, Lincoff AM, Kahn SE et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial. Lancet 2025; 40(10516)6 : 2257–2268. Dostupné z DOI:<http://dx.doi.org/10.1016/S0140–6736(25)01375–3>.

7. Wilson L, Zhao Z, Divino V et al. Semaglutide is associated with a lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice. Results from the STEER study. (Semaglutide and Tirzepatide Effects on Cardiovascular Outcomes in People With Overweight or Obesity in thE Real World). Eur Heart J 2025; 46(Suppl1).